Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Geron Corporation    GERN

GERON CORPORATION (GERN)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/15/2018 02/16/2018 02/20/2018 02/21/2018 02/22/2018 Date
2.38(c) 2.38(c) 2.24(c) 2.25(c) 2.23(c) Last
1 641 863 2 132 212 2 372 172 1 089 536 652 779 Volume
+3.93% 0.00% -5.88% +0.45% -0.89% Change
More quotes
Financials ($)
Sales 2017 1,15 M
EBIT 2017 -28,9 M
Net income 2017 -27,7 M
Debt 2017 -
Yield 2017 -
Sales 2018 30,8 M
EBIT 2018 -5,32 M
Net income 2018 -4,64 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 312x
Capi. / Sales2018 11,6x
Capitalization 358 M
More Financials
Company
Geron Corp. operates as a biotechnology company.It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.The company was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.  
More about the company
Surperformance© ratings of Geron Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on GERON CORPORATION
02/22Geron Announces Conference Call to Discuss Fourth Quarter and Annual 2017 Fin..
GL
02/02GERON CORP : Change in Directors or Principal Officers, Financial Statements and..
AQ
01/30GERON CORPORATION : Today’s Research Reports on Trending Tickers: Geron Corporat..
AC
01/08GERON CORP : Results of Operations and Financial Condition, Regulation FD Disclo..
AQ
2017GERON : Reports Imetelstat Presentations at American Society of Hematology Annua..
AQ
2017GERON CORP : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2017Geron Reports Imetelstat Presentations at American Society of Hematology Annu..
GL
2017GERON : to Host Analyst and Investor Meeting and Webcast on December 19, 2017
AQ
2017GERON CORPORATION : Today’s Research Reports on Trending Tickers: Geron Corporat..
AC
2017Geron to Host Analyst and Investor Meeting and Webcast on December 19, 2017
GL
More news
Sector news : Bio Therapeutic Drugs
02/22SANGAMO THERAPEUTICS : Surges on Therapy Collaboration Deal with Kite -- Market ..
DJ
02/22Sangamo in $3 billion gene-editing deal with Gilead
RE
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
02/22$GERN Geron Announces Conference Call to Discuss Fourth Quarter and Annual 20.. 
02/22Geron Announces Conference Call to Discuss Fourth Quarter and Annual 2017 Fin.. 
02/22Could Louisville football have 3 first-round NFL draft picks? Geron Christian.. 
02/22Could Louisville football have 3 first-round NFL draft picks? Geron Christian..
11
02/22$FLCR EXPLAIN HOW Georgetown property worth $5.5 million & we have a mark.. 
More tweets
Qtime:50
News from SeekingAlpha
02/20Imetelstat Might Be Brought Down By Hy's Law 
02/20THE NO BS PLAN : Week 1 Report 
02/14GERON : The Good, The Bad And The Ugly 
02/14It May Never Be Celgene, But It's A Mistake To Discount Geron 
02/12In This Stock Market, It's Time To Declare War On Biotech Bagholding 
Chart GERON CORPORATION
Duration : Period :
Geron Corporation Technical Analysis Chart | GERN | US3741631036 | 4-Traders
Technical analysis trends GERON CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 3,75 $
Spread / Average Target 67%
EPS Revisions
Managers
NameTitle
John A. Scarlett President, Chief Executive Officer & Director
Ho Young Huh Chairman
Olivia K. Bloom Chief Financial Officer, Treasurer & Executive VP
Karin Eastham Director
Robert Jay Spiegel Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
GERON CORPORATION24.44%358
GILEAD SCIENCES12.98%105 375
VERTEX PHARMACEUTICALS7.42%39 931
REGENERON PHARMACEUTICALS-14.08%34 113
BIOVERATIV INC92.71%11 243
GENMAB-0.97%10 344